Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Eoin Flanagan MB, BCh

Eoin P. Flanagan MB, BCh

Professor of Neurology; Division Chair in Multiple Sclerosis and Autoimmune Neurology; Autoimmune Neurology Fellowship Director, Departments of Neurology & Laboratory Medicine and Pathology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota

Dr Eoin Flanagan is a Professor of Neurology, Chief of the Division of Multiple Sclerosis and Autoimmune Neurology, Director of the Autoimmune Neurology Fellowship and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN). He completed his medical school training at University College Dublin in Ireland. He completed neurology residency, fellowships in neuroimmunology and a masters in clinical and translational science at Mayo Clinic (Rochester, MN). He works in the Autoimmune Neurology and Multiple Sclerosis Clinics and the Neuroimmunology Laboratory at the Mayo Clinic. His clinical expertise and research is focused on Myelin Oligodendrocyte Glycoprotein (MOG) antibody associated disease (MOGAD), aquaporin-4 antibody positive neuromyelitis optica spectrum disorders (NMOSD), transverse myelitis and other myelopathies, autoimmune encephalitis, paraneoplastic neurologic disorders and multiple sclerosis. He is principal investigator on an NIH RO1 grant studying MOGAD and was a member of the International MOGAD Panel that devised its diagnostic criteria.


Dr. Flanagan is a site principal investigator in a randomized placebo-controlled clinical trial of Inebilizumab (A CD19 inhibitor) in neuromyelitis optica spectrum disorders funded by MedImmune/Viela Bio. He receives no personal compensation and just receives reimbursement for the research activities related to the trial.